Status:
UNKNOWN
Multi Neuro-functional Biomarkers for Monitoring the Effects of Treatments in ADHD Children
Lead Sponsor:
IRCCS Eugenio Medea
Conditions:
Attention Deficit Hyperactivity Disorder
Eligibility:
All Genders
6-18 years
Phase:
PHASE4
Brief Summary
MIMOSA study aims to characterize from behavioral, neurophysiological and neurocognitive perspectives children and adolescents with attention deficit hyperactivity disorder (ADHD), in order to identif...
Eligibility Criteria
Inclusion
- diagnosis of ADHD according to DSM-5 (Diagnostic and Statistical Manual of Mental Disorders-5) criteria;
- drug naive
Exclusion
- presence of intellectual disability, neurological diseases, epilepsy, genetic syndromes
- and previous treatment with psychoactive drugs
Key Trial Info
Start Date :
April 13 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04272021
Start Date
April 13 2018
End Date
December 1 2023
Last Update
August 5 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS Eugenio Medea
Bosisio Parini, Italy